{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:29:36Z","timestamp":1779892176643,"version":"3.53.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07571-3","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T11:04:07Z","timestamp":1766833447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Meta-analysis of comparing CAR-T and bispecific antibody therapy in relapsed\/refractory indolent B-cell non-Hodgkin\u2019s lymphomas"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3393-215X","authenticated-orcid":false,"given":"Min-Yue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Mei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"7571_CR1","doi-asserted-by":"crossref","unstructured":"Kordic A, Phillips TJ, Weiss J. The Current State of bispecific antibodies and T-Cell directed therapy in NHL. Cancers (Basel). 2025;17(7).","DOI":"10.3390\/cancers17071192"},{"issue":"4","key":"7571_CR2","doi-asserted-by":"publisher","first-page":"101601","DOI":"10.1016\/j.beha.2025.101601","volume":"37","author":"IJ Tatake","year":"2024","unstructured":"Tatake IJ, Arnason JE. CARs for lymphoma. Best Pract Res Clin Haematol. 2024;37(4):101601.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"7571_CR3","doi-asserted-by":"publisher","first-page":"e473302","DOI":"10.1200\/EDBK-25-473302","volume":"45","author":"IA Nizamuddin","year":"2025","unstructured":"Nizamuddin IA, Ghobadi A. Chimeric antigen receptor T-Cell therapy and bispecific antibody use in earlier lines of treatment of large B-Cell lymphoma, follicular lymphoma, and Mantle Cell lymphoma. Am Soc Clin Oncol Educ Book. 2025;45(3):e473302.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"7571_CR4","doi-asserted-by":"publisher","first-page":"101598","DOI":"10.1016\/j.beha.2025.101598","volume":"37","author":"GM Gerhard","year":"2024","unstructured":"Gerhard GM, von Keudell G. Bispecific antibody therapy for lymphoma. Best Pract Res Clin Haematol. 2024;37(4):101598.","journal-title":"Best Pract Res Clin Haematol"},{"key":"7571_CR5","doi-asserted-by":"publisher","first-page":"104752","DOI":"10.1016\/j.critrevonc.2025.104752","volume":"212","author":"L Han","year":"2025","unstructured":"Han L, Wang K, Jiang Z, Guo X, Yu J. Recent development in bispecific antibody immunotherapy for hematological malignancies. Crit Rev Oncol Hematol. 2025;212:104752.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"7571_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/10428194.2025.2456970","volume":"66","author":"PL Fedele","year":"2025","unstructured":"Fedele PL, Opat S. Indolent lymphoma: addressing the needs of survivors. Leuk Lymphoma. 2025;66(6):1021\u201335.","journal-title":"Leuk Lymphoma"},{"key":"7571_CR7","doi-asserted-by":"crossref","unstructured":"Serroukh Y, Montoto S. Indolent lymphoma. In: Sureda A, Corbacioglu S, Greco R, Kr\u00f6ger N, Carreras E, editors. The EBMT Handbook: hematopoietic cell transplantation and cellular. Therapies. edn. Cham (CH): Springer Copyright; 2024. 2024, The Author(s)p. 763\u201369.","DOI":"10.1007\/978-3-031-44080-9_84"},{"issue":"10438","key":"7571_CR8","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","volume":"403","author":"E Silkenstedt","year":"2024","unstructured":"Silkenstedt E, Salles G, Campo E, Dreyling M. B-cell non-Hodgkin lymphomas. Lancet. 2024;403(10438):1791\u2013807.","journal-title":"Lancet"},{"key":"7571_CR9","doi-asserted-by":"crossref","unstructured":"Zhuang TZ, Zhang C, Strati P. SOHO State of the art updates and next questions | novel immunotherapy combinations for the treatment of indolent B-Cell lymphoma. Clin Lymphoma Myeloma Leuk. 2025.","DOI":"10.1016\/j.clml.2025.01.021"},{"issue":"15","key":"7571_CR10","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1200\/JCO.20.03433","volume":"39","author":"NH Fowler","year":"2021","unstructured":"Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA, et al. Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol. 2021;39(15):1609\u201318.","journal-title":"J Clin Oncol"},{"issue":"14","key":"7571_CR11","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331\u201344.","journal-title":"N Engl J Med"},{"issue":"11","key":"7571_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"issue":"9","key":"7571_CR13","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u201316.","journal-title":"ANZ J Surg"},{"issue":"Supplement 1","key":"7571_CR14","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/blood-2024-194612","volume":"144","author":"NL Bartlett","year":"2024","unstructured":"Bartlett NL, Sehn LH, Assouline SE, Giri P, Kuruvilla J, Schuster SJ, et al. Subcutaneous mosunetuzumab leads to High rates of durable responses, Low rates of cytokine release syndrome, and non-inferior Exposure compared with intravenous administration in patients with Relapsed\/Refractory follicular lymphoma: primary analysis of a pivotal phase II. Blood. 2024;144(Supplement 1):1645.","journal-title":"Blood"},{"issue":"8","key":"7571_CR15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055\u201365.","journal-title":"Lancet Oncol"},{"issue":"2","key":"7571_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325\u201332.","journal-title":"Nat Med"},{"issue":"2","key":"7571_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10147-024-02662-5","volume":"30","author":"H Goto","year":"2025","unstructured":"Goto H, Kumode T, Mishima Y, Kataoka K, Ogawa Y, Kanemura N, et al. Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed\/refractory follicular lymphoma: FLMOON-1. Int J Clin Oncol. 2025;30(2):389\u201396.","journal-title":"Int J Clin Oncol"},{"issue":"Supplement 1","key":"7571_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1182\/blood-2023-184883","volume":"142","author":"G Iacoboni","year":"2023","unstructured":"Iacoboni G, Serna A, Navarro Garces V, Jimenez Ubieto A, Valencia E, Lopez Garcia A, et al. Impact of prior bendamustine exposure on bispecific antibody treatment outcomes for patients with B-cell lymphoma. Blood. 2023;142(Suppl 1):310.","journal-title":"Blood"},{"issue":"S2","key":"7571_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/hon.3164_271","volume":"41","author":"C Jacobson","year":"2023","unstructured":"Jacobson C, Hemmer MT, Hu Z, Frank M, Popplewell L, Ahmed N, et al. Real-World early outcomes of axicabtagene ciloleucel for relapsed or refractory (R\/R) follicular lymphoma (FL). Hematol Oncol. 2023;41(S2):375\u201376.","journal-title":"Hematological Oncol"},{"issue":"1","key":"7571_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91\u2013103.","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"7571_CR21","doi-asserted-by":"publisher","first-page":"862\u2013","DOI":"10.1182\/blood-2024-200190","volume":"144","author":"TM Kim","year":"2024","unstructured":"Kim TM, Cho S-G, Taszner M, Chong G, Cai J, Uppala A, et al. Efficacy and safety of Odronextamab in Relapsed\/Refractory marginal zone lymphoma (R\/R MZL): data from the R\/R MZL cohort in the ELM-2 study. Blood. 2024;144(Supplement 1):862.","journal-title":"Blood"},{"issue":"11","key":"7571_CR22","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","volume":"35","author":"TM Kim","year":"2024","unstructured":"Kim TM, Taszner M, Novelli S, Cho SG, Villasboas JC, Merli M, et al. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. Ann Oncol. 2024;35(11):1039\u201347.","journal-title":"Ann Oncol"},{"issue":"Supplement 1","key":"7571_CR23","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1182\/blood-2024-204207","volume":"144","author":"DJ Landsburg","year":"2024","unstructured":"Landsburg DJ, Maziarz RT, Moskop A, Popplewell LL, Solomon SR, Tees MT, et al. Efficacy and safety of Tisagenlecleucel in patients with relapsed\/refractory follicular lymphoma: a real-world analysis from the center for blood and marrow transplant research (CIBMTR) Registry. Blood. 2024;144(Suppl 1):4398.","journal-title":"Blood"},{"issue":"8","key":"7571_CR24","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","volume":"11","author":"KM Linton","year":"2024","unstructured":"Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11(8):e593\u2013605.","journal-title":"Lancet Haematol"},{"key":"7571_CR25","unstructured":"Martinez-Cibrian N, Ortiz-Maldonado V, Brillembourg H, Alserawan L, Espa\u00f1ol-Rego M, Benitez-Ribas D, et al. Varnimcabtagene autoleucel (var-cel or ari-0001) in relapsed\/refractory adult follicular lymphoma. In: EHA. Spain; 2024."},{"issue":"Supplement 1","key":"7571_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/blood-2021-148778","volume":"138","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Carlo-Stella C, Dickinson M, Phillips T, Houot R, Offner F, et al. Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R\/R) follicular lymphoma (FL). Blood. 2021;138(Suppl 1):128.","journal-title":"Blood"},{"issue":"8","key":"7571_CR27","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","volume":"30","author":"F Morschhauser","year":"2024","unstructured":"Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 transcend FL study. Nat Med. 2024;30(8):2199\u2013207.","journal-title":"Nat Med"},{"key":"7571_CR28","doi-asserted-by":"crossref","unstructured":"Palomba M, Schuster S, Karmali R, Skarbnik A, Abramson J, Ardeshna K, et al. Lisocabtagene Maraleucel (LISO-CEL) in patients (pts) with relapsed or refractory (R\/R) marginal zone lymphoma (MZL) in the phase 2 transcend FL study. Hematol Oncol. 2025;43.","DOI":"10.1002\/hon.70093_55"},{"issue":"Supplement 1","key":"7571_CR29","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1182\/blood-2024-203753","volume":"144","author":"J Sharp","year":"2024","unstructured":"Sharp J, Strati P, Bhatta S, Huang JJ, Thomas C, Reef DK, et al. Evaluation of outcomes and toxicities of commercial axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for relapsed or refractory (R\/R) follicular lymphoma (FL): real-World evidence (RWE) from 10 us Academic centers. Blood. 2024;144(Suppl 1):2377 .","journal-title":"Blood"},{"issue":"12","key":"7571_CR30","doi-asserted-by":"publisher","first-page":"E436","DOI":"10.1002\/ajh.26711","volume":"97","author":"Z Ying","year":"2022","unstructured":"Ying Z, Zou D, Yang H, Wu J, Guo Y, Li W, et al. Preliminary efficacy and safety of relmacabtagene autoleucel (carteyva) in adults with relapsed\/refractory follicular lymphoma in China: a phase I\/II clinical trial. Am J Hematol. 2022;97(12):E436\u20138.","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"7571_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2023-184653","volume":"142","author":"L Ysebaert","year":"2023","unstructured":"Ysebaert L, Houot R, Casasnovas O, Sylvain C, Jardin F, Loschi M, et al. Real-word experience of car T-Cells in patients with Relapsed\/Refractory follicular lymphoma: a descart Registry analysis from the Lysa. Blood. 2023;142(Supplement 1):296.","journal-title":"Blood"},{"key":"7571_CR32","unstructured":"Zhou K, Xie Y, Li Z, Liang A, Tao R, Zhang J, et al. TQB2825, a novel 2: 1 structured CD20xCD3 bispecific antibody, in the relapsed\/refractory follicular lymphoma. In: EHA. Italy; 2025."},{"issue":"6","key":"7571_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/blood.2023023419","volume":"144","author":"J Kim","year":"2024","unstructured":"Kim J, Cho J, Lee MH, Yoon SE, Kim WS, Kim SJ. Car T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis. Blood. 2024;144(6):629\u201338.","journal-title":"Blood"},{"issue":"1","key":"7571_CR34","first-page":"e77.1","volume":"30","author":"CA Jacobson","year":"2024","unstructured":"Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, et al. Real-World outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis. Transpl Cell Ther. 2024;30(1):.e77.1\u2013.15.","journal-title":"Transpl Cell Ther"},{"key":"7571_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ejca.2021.10.022","volume":"160","author":"J Lemoine","year":"2022","unstructured":"Lemoine J, Vic S, Houot R. Disease-specific outcomes after chimeric antigen receptor T-cell therapy. Eur J Cancer. 2022;160:235\u201342.","journal-title":"Eur J Cancer"},{"issue":"2","key":"7571_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.5045\/br.2022.2021145","volume":"57","author":"AM Greenbaum","year":"2022","unstructured":"Greenbaum AM, Fromm JR, Gopal AK, Houghton AM. Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8(+) T-cells despite immune checkpoint signaling. Blood Res. 2022;57(2):117\u201328.","journal-title":"Blood Res"},{"issue":"1","key":"7571_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40164-025-00610-1","volume":"14","author":"LJ Nastoupil","year":"2025","unstructured":"Nastoupil LJ, Bonner A, Wang P, Almuallem L, Desai J, Farazi T, et al. Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma. Exp Hematol Oncol. 2025;14(1):30.","journal-title":"Exp Hematol Oncol"},{"issue":"9","key":"7571_CR38","first-page":"e885.1","volume":"30","author":"MD Ray","year":"2024","unstructured":"Ray MD, Kanters S, Beygi S, Best T, Wulff J, Limbrick-Oldfield E, et al. Matching-adjusted indirect comparisons of Axicabtagene Ciloleucel to mosunetuzumab for the treatment of Relapsed\/Refractory follicular lymphoma. Transpl Cell Ther. 2024;30(9):.e885.1\u2013.11.","journal-title":"Transpl Cell Ther"},{"issue":"Supplement 1","key":"7571_CR39","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2024-197902","volume":"144","author":"LE Budde","year":"2024","unstructured":"Budde LE, Matasar M, Sehn LH, Assouline SE, Kuruvilla J, Flinn IW, et al. Mosunetuzumab monotherapy demonstrates encouraging activity and a manageable safety profile in patients with heavily pre-treated relapsed or refractory Mantle cell lymphoma. Blood. 2024;144(Supplement 1):1646.","journal-title":"Blood"},{"key":"7571_CR40","doi-asserted-by":"crossref","unstructured":"Alhomoud M, Ibrahim R, Demetres M, Rejeski K, Scordo M, Shouval R, et al. Safety and efficacy of bridging radiation therapy prior to CD19 car T for non-Hodgkin lymphoma: a systematic review and meta-analysis. Haematologica. 2025.","DOI":"10.3324\/haematol.2025.287547"},{"key":"7571_CR41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.radonc.2022.10.018","volume":"177","author":"Q Yu","year":"2022","unstructured":"Yu Q, Zhang X, Wang N, Li C, Zhang Y, Zhou J, et al. Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed\/refractory aggressive B-cell lymphoma. Radiother Oncol. 2022;177:53\u201360.","journal-title":"Radiother Oncol"},{"issue":"Supplement 1","key":"7571_CR42","doi-asserted-by":"publisher","first-page":"1016\u2013","DOI":"10.1182\/blood-2023-185216","volume":"142","author":"M Alhomoud","year":"2023","unstructured":"Alhomoud M, Foley M, Sugita M, Yamazaki T, Martinez L, Yamshon S, et al. Low dose total body irradiation improves CD19 CAR-T expansion, persistence, and trafficking, leading to enhanced efficacy in large B-Cell lymphoma. Blood. 2023;142(Suppl 1):1016.","journal-title":"Blood"},{"key":"7571_CR43","doi-asserted-by":"crossref","unstructured":"van Besien Hj, Easwar N, Demetres M, Pasciolla M, Shore T, Leonard JP, et al. Comparative infection risk in CAR T vs bispecific antibodies in B cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2025 .","DOI":"10.1016\/S2152-2650(25)01481-8"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07571-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07571-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07571-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:14:02Z","timestamp":1769602442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07571-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7571"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07571-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}